Pathophysiology of Immune Checkpoint Inhibitor-Induced Myocarditis
Immune checkpoint inhibitors (ICIs) have recently emerged as strong therapies for a broad spectrum of cancers being the first-line treatment for many of them, even improving the prognosis of malignancies that were considered untreatable. This therapy is based on the administration of monoclonal anti...
Main Authors: | Rosa Jiménez-Alejandre, Ignacio Ruiz-Fernández, Pilar Martín |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-09-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/14/18/4494 |
Similar Items
-
Immune Checkpoint Inhibitor-Associated Myocarditis
by: Grigorios Chatzantonis, MD, et al.
Published: (2020-04-01) -
Incidence and Distinct Features of Immune Checkpoint Inhibitor-Related Myositis From Idiopathic Inflammatory Myositis: A Single-Center Experience With Systematic Literature Review and Meta-Analysis
by: Naoki Hamada, et al.
Published: (2021-12-01) -
A case of subclinical immune checkpoint inhibitor-associated myocarditis in non-small cell lung cancer
by: Yue Hu, et al.
Published: (2023-04-01) -
Case report: Electrocardiographic changes in pembrolizumab-induced fatal myocarditis
by: Kazuhiro Nishiyama, et al.
Published: (2023-02-01) -
Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment
by: Nicolas Palaskas, et al.
Published: (2020-01-01)